Carmegliptin; 813452-18-5; Camegliptin; RO4876904; 9Z723VGH7J; CHEMBL591118; R1579; R-1579; (4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one; Ro-4876904; (4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one; 2-Pyrrolidinone, 1-((2S,3S,11bS)-2-amino-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizin-3-yl)-4-(fluoromethyl)-, (4S)-; Carmegliptin [USAN]; Carmegliptin [USAN:INN]; UNII-9Z723VGH7J; (4S)-1-((2S,3S,11bS)-2-Amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido(2,1-a)isoquinolin-3-yl)-4-(fluoromethyl)pyrrolidin-2-one; Carmegliptin (USAN/INN); CARMEGLIPTIN [INN]; CARMEGLIPTIN [WHO-DD]; SCHEMBL419289; DTXSID401001938; BDBM50309470; ZINC38358483; DB12268; (S)-1-((2S,3S,11bS)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-3-yl)-4-(fluoromethyl)pyrrolidin-2-one; D08631; Q27273409; (S)-1-((S,S,S)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido [2,1-a]isoquinolin-3-yl)-4-fluoromethyl-pyrrolidin-2-one; 1-(2-Amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4-(fluoromethyl)pyrrolidin-2-one; B1Q